Generex BIOTECHNOLOGY"

An Integrated Healthcare Holding Company (GNBT:OTCQB)

January 2019

Disclaimers

SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS

This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding future results of operations, business strategy, current and prospective product candidates, planned clinical trials and preclinical activities, product approvals, timing and likelihood of success, plans and objectives of management for future operations, and future results of anticipated product candidates, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

NO OFFER OR SOLICIATION

This presentation is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities in any jurisdiction pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer or sale of securities shall be made except in a private placement in reliance upon the exemption from securities registration afforded by Section 4(2) of the Securities Act of 1933, as amended (the "Securities Act"), and Rule 506 of Regulation D under the Securities Act. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the offer of securities will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.




An Integrated Pharmaceutical Healthcare Company

CORPORATE MISSION:

To provide physicians, hospitals, and all healthcare providers with an end-to-end solution for patient centric care from rapid diagnosis through delivery of personalized therapies, streamlining care processes, minimizing expenses, and delivering transparency for payers.



Generex is Reorganized as a Multi-Disciplined Healthcare Holding Company




EXECUTE on Strategy

- Strategic acquisitions
 - Synergistic alliances
- Commercial development
- Revenue-generating licensing agreements
- Long-term portfolio value through diversification

Building Value for Investors, Shareholders, and Partners




Generex Biotechnology Holding Corporation Is Structured To Optimize Revenue For Shareholders



The NuGenerex Organizational Structure Combines **Revenue Generating** Healthcare Management Services and Distribution Organizations with **Value Driving**, Cutting-edge R&D Companies



NuGenerex Distribution Solutions Generates Significant Revenues, Profit, And Value For Investors





NuGenerex Medical Marketing & Pharmacy Network Enhance the Capabilities Of the Rapport MSO




OUR CAPABILITIES

Pharmacy	Laboratory	Biologics	DME-IQ
Patient assistance	Pharmacogenetic testing	AATB certified products	Deep vein thrombosis
programs	 Toxicology assistance 	• Human tissue based	Cardiac
 Prescription plans 	• Extensive pathology testing	biologic treatment	
Local Rx delivery	 Allergy tests 		
Community services			




Powerful Synergies & Add-ons Drive Future Performance







Multiple Avenues For Near And Longer-Term Sustainable Growth





Rapport Services Pre-Generex Acquisition





- 5 states
- Multiple MSO's
- Focus on Non Opioid Topical Creams (scar, migraine, antifungal, and wound creams)
- Declining Reimbursements
- No tradeable securities
- Cloud of Investigation



Rapport Services Post-Generex Acquisition

Increasing the Value of the Rapport Network



Generex Acquisitions: Drug & Device Products for Rapport

DMEiq – Orthopedic Products & Services Olaregen – Excellagen for Wound Healing Regentys - Extracellular Matrix for Ulcerative Colitis



- One Large Fully-compliant MSO
- Expansion into a total of 27 states with the Rapport model
- Adding specialty MSOs to expand Rapport service offerings
- Expanded laboratory services
- Specialty product pricing for Rapport network



Generex Subsidiaries Provide Opportunities For Substantial Longer-Term ROI



NGenerex subsidiaries develop life-changing products including medical devices, therapeutics, and diagnostics that can complement MSO services and product offerings and drive corporate value.









NuGenerex Has Reorganized its Asset Portfolio Targeting High-Growth Fields of Diabetes, Immunotherapy, and Infectious Disease



NuGenerex Immuno-Oncology

- Vaccines built on li-Key technology
- Focusing on stimulating CD-4 and CD-8 T-Cells
- Planned Phase II trial with AE37 and Keytruda combination for TNBC
- Partnership with Shenzhen BioScien to develop and commercialize AE37 for prostate cancer
 - \$700k up-front license fee
 - Up to \$4 MM milestone payments
 - 10% royalty on commercial sales



NuGenerex Therapeutics

- Developing next-gen drugs for diabetes, oncology and infectious diseases
- Oral-lyn, buccal insulin delivery system, for the treatment of type 2 diabetes
- RapidMist buccal delivery system exploring other applications for the technology
 - Partnership with Scientus Pharma for cannabis administration

NuGenerex Diagnostics


NuGenerex

DIAGNOSTICS

- Point of care diagnostic tests for HIV, tuberculosis, malaria, hepatitis, syphilis, and other infectious diseases
- Rapid immunochromatographic diagnostics can produce results in as little as 10-15 min
- Developing a new and novel multiplex assay designed for Sepsis and SIRS



NuGenerex Immuno-Oncology (Formerly Antigen Express) Capitalizes on the Growth of Cancer Immunotherapy



The Cancer Immunotherapy Market was \$45 Billion in 2015, and is estimated to reach \$117 Billion by 2022



Cancer Immunotherapy Is A High-Value Business Opportunity with \$45 Billion In Sales In 2015

The Total Valuation of the Top 10 Cancer Immunotherapy Deals in 2018 is \$35.5 Billion

AE37 + Merck's Keytruda in TNBC NuGenerex Immuno-Oncology Revenue Opportunity

Treatment Cost of \$50k / year	Year	Market Share	Breast	тивс	Metastatic TNBC
Independent 3 rd party analysis for New TNBC Treatment*	1	2.0%	\$470M	\$188M	\$89M
	2	7.0%	\$1.48B	\$592M	\$281M
	3	14%	\$3.13B	\$1.25B	\$592M
FORESIGHT	4	24%	\$3.38B	\$1.35B	\$1B
	5	39%	\$8.45B	\$3.38B	\$1.6B


BMS reported yearly sales of \$4.9bn from Opdivo and \$1.2bn from Yervoy while Merck generated \$3.8bn from Keytruda - GEN



NuGenerex Ii-Key Technology Platform: *First-in-class Self-Potentiating Active Immunotherapy*




LI-KEY PEPTIDE STRUCTURE AND FUNCTION



li-Key Locks Antigenic Peptides In MHC Class II Binding Site

AE37 MECHANISM OF ACTION




AE37 (Ii-Key/HER2/neu) Ii-Key immuno-therapeutic peptide activates CD4⁺ T-Cells to target & kill cancer cells



Treatment With AE37 Immuno-therapeutic Vaccine Resulted In Increased Disease Free Survival In Patients With TNBC



Phase II Trial of AE37 – TNBC (ITT)





Mittendorf et al (2016) Ann Oncol, 27:1241-8

Key Value Drivers For NuGenerex Immuno-Oncology R&D

AE37 R&D Program - Checkpoint Inhibitors Reignite Development

- > Phase II will evaluate AE37/Keytruda combination in triple negative breast cancer
 - Collaboration with Merck supplying Keytruda
 - Trial to be conducted through the National Surgical Adjuvant Breast and Bowel
 Project cooperative group
- Licensing agreement with Shenzen BioScien for rights in China
 - Phase II Trial to evaluate AE37 in Prostate Cancer
 - NuGenerex secures data rights & maintains market for ROW
- Ii-Key Hybrid Peptide Immunotherapeutic Vaccines
 - Melanoma: GP100 (48-58); Tyr (370-381)
 - Antigen Identification Program with Data Analytics Rapid Pipeline Development
 - Multi-Valent epitope combinations



Developing Point-Of-Care Diagnostic Products to Meet Today's Challenges in Infectious Diseases




Advancing Diagnostic Testing for Personalized Medicine

NGDx-Express II[™] Platform Value Drivers

NGDx-Express II™ Development

- Needs only whole blood specimens taken via finger-stick, venipuncture, or processed serum
- No need to transfer blood to the device via pipette
- Test results available in 15-30 min
- · Easy to use with only three operator steps
- Clear visual readout
- Can be used for multiple test analytes
- Designed to eliminate cross-contamination and are completely safe for home use
- Can be cheaply and efficiently manufactured





Adding Target Acquisitions in Diabetes, Concussion Dx & Clinical Laboratory For Pharmaco-Genomic Testing

NuGenerex's RapidMist technology is in development to improve current methods to deliver insulin and cannabinoids



Oral-Lyn for Buccal-Administered Insulin

- Evaluated in over 600 subjects with Type 1 & 2 diabetes and healthy volunteers
 - Shown to be efficacious and safe
- Collaboration with University Health Network to increase insulin bioavailability to reduce the number of puffs required to achieve effective prandial metabolic control

RapidMist Technology

- Uses a chemical propellant to aerosolize and administer compound for buccal absorption
- Collaboration with Scientus Pharma to develop a buccal cannabis spray using RapidMist technology
 - Scientus recently announced renewed focus on developing buccal cannabis having recently received authorization to produce cannabis soft-gel capsules and oils





Acquisitions of Companies with FDA Approved Products and Great Management Strengthens NuGenerex's Portfolio



NuGenerex Acquisition of Olaregen Therapeutix (Nov 2018)

- Access to Excellagen[®] advanced wound care management platform, FDA-approved for 17 indications including:
 - Surgical Incisions
 - Diabetic Foot Ulcers
 - Venous & Arterial Ulcers
 - Mohs Surgery
 - Wound Repair

Excellagen 2019 Product Launch

- Commercialization through NuGenerex Distribution Solutions' MSO & pharmacies network of podiatrists & diabetologists
- Existing contracts with two national wound care centers





Generex Aims to Acquire Advanced Technologies That Fill Gaps in Specialty Medical Care



Acquisition Target: Regentys


Regentys is developing a novel Extracellular Matrix Hydrogel product aimed at coating the intestinal layer in order to address a variety of GI-related diseases

Extracellular Matrix Hydrogel Targets

- Inflammatory bowel disease
- Ulcerative colitis
- Chrohn's disease (>\$bn market opportunity 1.1mn US patients)

Clinical Development Pathway

- 1st indication: ulcerative colitis
- FDA 510K de novo pathway
- Clinical trials currently ongoing





Generex BIOTECHNOLOGY"

An Integrated Healthcare Holding Company (GNBT:OTCQB)

December 2018